News

Cannabis: A secret weapon against superbugs

Arti Dumbrepatil
Nov. 5, 2020

Although the novel coronavirus has grabbed most headlines in recent months, antimicrobial resistance remains a critical challenges for public health agencies around the world, notably the rapid spread of methicillin-resistant Staphylococcus aureus, known as MRSA. In the fight against this superbug, Eric Brown employs an unconventional research approach, developing novel drug molecules from natural products, specifically from Cannabis sativa.

“Natural products have the potential to solve the issue of drug resistance in pathogenic bacteria,” Brown said. “This is a great resource that we haven’t fully investigated. Researchers in academia have the tools and ability to pursue outlandish ideas, which can be steered to the development of new therapeutic agents.”

As the Canada research chair in microbial chemical biology and a professor of biochemistry and biomedical sciences at McMaster University, Brown leads an interdisciplinary research team that has detected a cannabinoid called cannabigerol or CBG.

“Cannabis plants are known to produce compounds to block the invading pathogens,” Brown said. “We decided to take benefit of the regulatory environment in Canada and use Cannabis to tackle the emerging threat of drug resistance.”

Since the 2018 legalization of marijuana in Canada, Brown’s lab has been studying the antibiotic potential of cannabis. This research has some stigma associated with it, Brown said, but there is circumstantial evidence for medicinal use of the plant. The team established the antibacterial properties of CBG and found that it was highly effective at controlling MRSA in mice. Controlling MRSA is challenging as it is resistant to all known beta-lactam antibiotics. Further, the lab’s study published in the journal American Chemical Society Infectious Diseases found that CBG targeted the cell membrane of bacteria and prevented formation of biofilms, bacterial communities that adhere to each other and surfaces, and also destroyed existing biofilms.

Brown-lab-890x489.jpg
Courtesy of the Brown Lab
From left, postdoctoral fellow Omar El-Halfawy, Eric Brown, and research associate Maya Farha are authors of the lab’s study of CBG.

The team also demonstrated the potential of CBG in combination with antibiotic therapy to combat increasing instances of drug resistance in bacteria. CBG with polymyxin B inhibited the growth of Gram-negative pathogens that are resistant to multiple drugs, such as Acinetobacter baumannii, Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa, revealing the broad-spectrum therapeutic potential for cannabinoids. But the compound is not without drawbacks.

“CBG is great at attacking pathogenic bacteria; however, it is toxic to host cells,” Brown said. “Further research and development are needed to ultimately have a safe drug for therapeutic purposes.”

Although the lab has developed creative chemical-biology approaches to characterize novel antimicrobial compounds from natural products, they face additional challenges. “A major hurdle in natural product drug discovery is the chemical synthesis of these molecules,” Brown said.

For this, they collaborated with Jakob Magolan, a McMaster associate professor of biochemistry and biomedical sciences whose research focuses on using organic synthetic chemistry in drug development. “When you take an unusual research project,” Brown said, “it is great to have a team with complementary expertise, as it helps to advance the field (by) rapidly overcoming hurdles.”

Brown hopes to pursue the commercialization of CBG in collaboration with partners in the pharma industry.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Arti Dumbrepatil

Arti Dumbrepatil is a freelance science writer and communicator. With her academic training plus expertise in science communication and writing, she demystifies and transforms complex, jargon-filled science into enjoyable and comprehensible content that resonates with a diverse audience. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Gene-mutation pathway discovery paves way for targeted blood cancers therapies
News

Gene-mutation pathway discovery paves way for targeted blood cancers therapies

Nov. 3, 2024

A new study by researchers at the universities of Texas and Chicago explains the enzymatic activity that’s needed for tumor suppression in leukemias and other cancers.

Candy binges can overload your gut microbiome
News

Candy binges can overload your gut microbiome

Nov. 2, 2024

While most Halloween candies contain lots of sugar, some are better for your gut microbiome than others.

Water rescues the enzyme
Essay

Water rescues the enzyme

Oct. 31, 2024

“Sometimes you must bend the rules to get what you want.” In the case of using water in the purification of calpain-2, it was worth the risk.

Virtual issue celebrates water in ASBMB journals
Journal News

Virtual issue celebrates water in ASBMB journals

Oct. 30, 2024

Read a dozen gold open-access articles covering exciting research about the society’s 2024 Molecule of the year.

There are worse things in the water than E. coli
News

There are worse things in the water than E. coli

Oct. 29, 2024

E. coli levels determined whether Olympic swimmers could dive into the Seine this past summer. But are these bacteria the best proxy for water contamination?

Biobots arise from the cells of dead organisms
News

Biobots arise from the cells of dead organisms

Oct. 27, 2024

Given the right conditions, certain types of cells are able to self-assemble into new lifeforms after the organism they were once part of has died.